STING could be a potential therapeutic target that enhances anti-cancer immune response in CRC.Higher STING expression in CRC tissues was correlated with higher recurrence free and survival rates. The growth of tumor can be effectively suppressed after intratumoral STING agonist 3'3'-cGAMP by enhancing intratumoral infiltration and activation CD8+ T cells. The gene discussed is STING1; the disease is colorectal carcinoma.